On Tuesday, Spyre Therapeutics Inc (NASDAQ: SYRE) was -8.97% drop from the session before settling in for the closing price of $39.35. A 52-week range for SYRE has been $8.75 – $47.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -49.91% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 90.97%. With a float of $42.65 million, this company’s outstanding shares have now reached $51.43 million.
In an organization with 30 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 7.49%, operating margin of -18543.86%, and the pretax margin is -20619.19%.
Spyre Therapeutics Inc (SYRE) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Spyre Therapeutics Inc stocks. The insider ownership of Spyre Therapeutics Inc is 17.08%, while institutional ownership is 93.96%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -4.05 earnings per share (EPS) during the time that was less than consensus figure (set at -0.78) by -3.27. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.97% per share during the next fiscal year.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
You can see what Spyre Therapeutics Inc (SYRE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.46, a number that is poised to hit -1.05 in the next quarter and is forecasted to reach -4.23 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Let’s dig in a bit further. During the last 5-days, its volume was 0.68 million. That was better than the volume of 0.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.22%. Additionally, its Average True Range was 2.32.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 75.43%, which indicates a significant increase from 44.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.40% in the past 14 days, which was higher than the 58.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.16, while its 200-day Moving Average is $31.16. However, in the short run, Spyre Therapeutics Inc’s stock first resistance to watch stands at $38.91. Second resistance stands at $42.01. The third major resistance level sits at $43.75. If the price goes on to break the first support level at $34.07, it is likely to go to the next support level at $32.33. Assuming the price breaks the second support level, the third support level stands at $29.23.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
There are 51,431K outstanding shares of the company, which has a market capitalization of 1.84 billion. As of now, sales total 890 K while income totals -338,790 K. Its latest quarter income was 0 K while its last quarter net income were -69,030 K.
